Case Report: Treatment of Pulmonary Squamous Cell Carcinoma with Vispearl® Radiopaque Drug-Eluting Embolic Microspheres by Prof. Yue Kun’s Team at Jiren Hospital, Affiliated with the Second Clinical Medical College of Xi’an Jiaotong University

Jun 12, 2026 07:40 CST Updated 07:40

H&H Healthcare

R&D and Producer of Interventional Medical Devices for Heart Disease

Introduction

Lung cancer is a type of malignant tumor originating from the bronchial mucosal epithelial cells or glands., lung cancer has the highest mortality rate among all malignant tumorsPosition.

The 2023 Chinese Expert Consensus on Bronchial Artery Chemoembolization for the Treatment of Lung Cancer states that transarterial embolization of the blood supply to lung tumors using embolic agents can block tumor perfusion, thereby delaying drug washout from the target area, inducing ischemic hypoxia and necrosis in tumor tissue, and enhancing therapeutic efficacy. Drug-eluting microspheres can carry chemotherapeutic agents to prolong their action time while simultaneously embolizing the tumor.

HuiHe Healthcare’s radiopaque drug-eluting microspheres, Vispearl®, can meet diverse clinical needs. The radiopacity of Vispearl® not only allows for tracking of the drug-eluting microspheres during the procedure, but also enables immediate post-procedural assessment of embolization efficacy and localization of tumor lesions throughout follow-up.

This Issue’s Case Share: Professor Yue Kun’s Team from the Second Clinical Medical College of Xi’an Jiaotong University Affiliated Jiren Hospital Applies Vispearl^®A Case of Lung Squamous Cell Carcinoma Treated with Radiopaque Drug-Eluting Embolization Microspheres.

Professor Yue Kun's Team

Xi'an Jiaotong University

The Second Clinical Medical College Affiliated Jiren Hospital

Case Information

Basic Information: 78-year-old maleSex

Chief Complaint:Recurrent cough and sputum production for over 10 years, intermittent hemoptysis for 2 months

Past Medical History:Ten years ago, the patient underwent surgery and tracheostomy at an external hospital for malignant laryngeal tumor. Postoperatively, intermittent symptoms such as cough and sputum production occurred, which improved after symptomatic treatment.

Physical Examination:Breath sounds were coarse in the upper lobes of both lungs and diminished at the lung bases; scattered wheezes and dry rales were audible, particularly in the left lung.

Laboratory Tests:hs-CRP 14.1 mg/L; SAA 78.8 mg/L; IL-6 4.09pg/mL；NSE 8.17ng/mL；SCC 17.46 ng/mL；CEA 3.13 ng/mL

Imaging Examination:Left lower hilar mass,Occlusion of the left lower lobe bronchus,Consider central lung cancer

6月11日.gif

Pathological Examination:

Squamous cell carcinoma cells detected in sputum

Surgical Plan:

Diagnosis:Malignant tumor of the left lower lobe of the lung (cT3N1M0 Stage IIIA squamous cell carcinoma),Obstructive pneumonia,Occlusion of the left lower lobe bronchus with atelectasis.

Via MDTFormulationTreatment Plan: The tumor is located near the pulmonary hilum. The family refused surgical treatment. After communication with the family, the following was performed:D-BACE therapy,Assessment of Therapeutic Efficacy After Staged Treatment

Surgical Procedure

D-BACE Treatment: Superselective microcatheterization of the tumor-feeding arteries, followed by embolization using 100–300 μm radiopaque drug-eluting microspheres (Vispearl) loaded with 50 mg of doxorubicin.

Postoperative Follow-up

3-Month Postoperative Follow-up:

SCC 8.47ng/mL ;CEA 2.95 ng/mL

Imaging findings: Significant reduction in lesion size

Chemical Drug Perfusion Therapy:

Surgical Plan:

Bronchial Artery DSA, BACE if Necessary

Chemical Drug Perfusion (Protocol: Nedaplatin 50 mg)

Periodic Follow-up

Expert Profile

Yue Kun | Professor

Associate Chief Physician

Director, Department of Vascular and Oncological Intervention, Xi'an Jiren Hospital

Director of the Department of Vascular and Oncologic Intervention, Xi’an Jiren Hospital; Associate Chief Physician; Master of Medicine; Graduate of Air Force Medical University. With over ten years of experience in minimally invasive interventional therapy, he possesses extensive clinical expertise. He serves as a Committee Member of the Interventional Branch of the Shaanxi Provincial Medical Association; a Committee Member of the Young Professionals Group on Oncologic Intervention of the Shaanxi Anti-Cancer Association; a Committee Member of the Professional Committee on Interventional Medicine of the Shaanxi Association of Integrative Traditional Chinese and Western Medicine; a Committee Member of the Liver Tumor Multidisciplinary Team (MDT) Group under the Professional Committee on Multidisciplinary Collaborative Diagnosis and Treatment of Tumors of the Shaanxi Health Care Association; and a Member of the Asia-Pacific Vascular Alliance.

Huang Yu | Physician

Department of Vascular and Tumor Intervention, Xi'an Jiren Hospital

Graduated from the Clinical Medicine program at Xi’an Jiaotong University, currently serving as a physician in the Department of Vascular Tumor Intervention at Jiren Hospital, the Second Affiliated Clinical Medical College of Xi’an Jiaotong University. Member of the Deep Vein Thrombosis Prevention and Treatment Professional Group under the Peripheral Vascular Professional Committee of the Shaanxi Provincial Gerontology and Geriatrics Society; Member of the Minimally Invasive Oncology Branch of the Shaanxi Provincial Association of Integrative Traditional Chinese and Western Medicine; Member of the Interventional Medicine Branch of the Shaanxi Provincial Medical Communication Association. Specializes in the prevention, treatment, and interventional diagnosis and therapy of primary liver cancer and lower extremity arterial and venous thrombosis.

Vispearl^®Yingzhu^®Radiopaque Drug-Eluting Embolization Microspheres